Suppr超能文献

在一个多样化的感染HIV的女性前瞻性队列中评估单核苷酸多态性与替诺福韦暴露之间的关联。

Evaluating the association of single-nucleotide polymorphisms with tenofovir exposure in a diverse prospective cohort of women living with HIV.

作者信息

Baxi S M, Greenblatt R M, Bacchetti P, Cohen M, DeHovitz J A, Anastos K, Gange S J, Young M A, Aouizerat B E

机构信息

Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.

School of Public Health, University of California, Berkeley, Berkeley, CA, USA.

出版信息

Pharmacogenomics J. 2018 Apr;18(2):245-250. doi: 10.1038/tpj.2017.3. Epub 2017 May 2.

Abstract

Higher exposure to tenofovir (TFV) increases the risk for kidney function decline, but the impact of genetic factors on TFV exposure is largely unknown. We investigated whether single-nucleotide polymorphisms (SNPs, n=211) in 12 genes are potentially involved in TFV exposure. Participants (n=91) from the Women's Interagency HIV Study, underwent a 24 h intensive pharmacokinetic sampling of TFV after witnessed dose and TFV area under the time-concentration curves (AUCs) were calculated for each participant. SNPs were assayed using a combination of array genotyping and Sanger sequencing. Linear regression models were applied to logarithmically transformed AUC. Those SNPs that met an a priori threshold of P<0.001 were considered statistically associated with TFV AUC. ABCG2 SNP rs2231142 was associated with TFV AUC with rare allele carriers displaying 1.51-fold increase in TFV AUC (95% confidence interval: 1.26, 1.81; P=1.7 × 10). We present evidence of a moderately strong effect of the rs2231142 SNP in ABCG2 on a 24 h TFV AUC.

摘要

更高的替诺福韦(TFV)暴露量会增加肾功能下降的风险,但遗传因素对TFV暴露的影响在很大程度上尚不清楚。我们研究了12个基因中的单核苷酸多态性(SNP,共211个)是否可能与TFV暴露有关。来自女性机构间HIV研究的参与者(n = 91)在见证给药后接受了24小时的TFV强化药代动力学采样,并计算了每位参与者的TFV时间-浓度曲线下面积(AUC)。使用阵列基因分型和桑格测序相结合的方法对SNP进行检测。将线性回归模型应用于对数转换后的AUC。那些达到P<0.001的先验阈值的SNP被认为与TFV AUC有统计学关联。ABCG2 SNP rs2231142与TFV AUC相关,罕见等位基因携带者的TFV AUC增加了1.51倍(95%置信区间:1.26,1.81;P = 1.7×10)。我们提供了证据表明ABCG2中的rs2231142 SNP对24小时TFV AUC有中等强度的影响。

相似文献

3
Population Pharmacokinetic Modeling of Tenofovir in the Genital Tract of Male HIV-Infected Patients.
Antimicrob Agents Chemother. 2017 Feb 23;61(3). doi: 10.1128/AAC.02062-16. Print 2017 Mar.
4
Factors associated with daily tenofovir exposure in Thai subjects taking combination antiretroviral therapy.
AIDS Res Hum Retroviruses. 2015 Apr;31(4):368-74. doi: 10.1089/AID.2014.0249. Epub 2014 Dec 17.
6
Discovery of Genetic Variants of the Kinases That Activate Tenofovir in a Compartment-specific Manner.
EBioMedicine. 2015 Jul 9;2(9):1145-52. doi: 10.1016/j.ebiom.2015.07.008. eCollection 2015 Sep.
9
Methotrexate Decreases Tenofovir Exposure in Antiretroviral-Suppressed Individuals Living With HIV.
J Acquir Immune Defic Syndr. 2020 Dec 15;85(5):651-658. doi: 10.1097/QAI.0000000000002502.
10
Impact of pharmacogenetics and pregnancy on tenofovir and emtricitabine pharmacokinetics.
Pharmacogenomics. 2019 Mar;20(4):217-223. doi: 10.2217/pgs-2018-0111. Epub 2019 Feb 15.

引用本文的文献

1
Pharmacogenetics of tenofovir renal toxicity in HIV-positive Southern Africans.
Pharmacogenet Genomics. 2023 Jul 1;33(5):91-100. doi: 10.1097/FPC.0000000000000491. Epub 2023 Apr 24.
2
Important roles of transporters in the pharmacokinetics of anti-viral nucleoside/nucleotide analogs.
Expert Opin Drug Metab Toxicol. 2022 Jul-Aug;18(7-8):483-505. doi: 10.1080/17425255.2022.2112175. Epub 2022 Sep 9.
3
Pharmacogenetics of tenofovir and emtricitabine penetration into cerebrospinal fluid.
South Afr J HIV Med. 2021 Apr 28;22(1):1206. doi: 10.4102/sajhivmed.v22i1.1206. eCollection 2021.
4
Pharmacogenomics with red cells: a model to study protein variants of drug transporter genes.
Vox Sang. 2021 Feb;116(2):141-154. doi: 10.1111/vox.12999. Epub 2020 Sep 30.

本文引用的文献

4
A pharmacogenetic candidate gene study of tenofovir-associated Fanconi syndrome.
Pharmacogenet Genomics. 2015 Feb;25(2):82-92. doi: 10.1097/FPC.0000000000000110.
5
Should the dose of tenofovir be reduced to 200-250 mg/day, when combined with protease inhibitors?
J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19583. doi: 10.7448/IAS.17.4.19583. eCollection 2014.
9
Low body weight in females is a risk factor for increased tenofovir exposure and drug-related adverse events.
PLoS One. 2013 Dec 2;8(12):e80242. doi: 10.1371/journal.pone.0080242. eCollection 2013.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验